Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

resulting in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if available) in combination with flotetuzumab will be safe, tolerable and may provide additional

  • 0 views
  • 07 Oct, 2022
  • 1 location
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Adults

Donor Lymphocyte Infusion (DLI) following salvage chemotherapy is the one of the most widely used treatment approaches in patients who relapse after allogeneic hematopoietic cell transplant

  • 24 views
  • 21 Oct, 2022
  • 1 location
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

This pilot study is being conducted to treat patients who have a certain type of malignancy (lymphoid or myeloid) with immune effector cells after a T-cell depleted allogeneic hematopoietic cell transplantation (TCD HSCT). This study is designed to see whether an investigational cellular product of immune cells obtained from a …

cell transplantation
  • 0 views
  • 05 Jun, 2022
  • 1 location
Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy

Allo-hsct is potentially curative method of treatment for children and adolescent with hematologic malignancy. However, relapses of disease after allo-hsct occur up to 50% of patients and constitute the main cause of mortality after HSCT. Donor lymphocytes infusion (DLI) is a form of immunotherapy based on developement of reaction "graft …

chronic myeloid leukemia
leukemia
donor lymphocyte infusion
hematologic malignancy
myeloid leukemia
  • 0 views
  • 22 Aug, 2021
  • 1 location
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients With MDA and Secondary AML

The purpose of the study is to determine the safety of an investigational treatment for myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine) stops working or after progression of MDS to acute myeloid leukemia (AML). Funding source - FDA OOPD.

acute promyelocytic leukemia
anemia
secondary acute myeloid leukemia
myeloid leukemia
cytarabine
  • 0 views
  • 18 Oct, 2022
  • 1 location
Extracorporeal Photopheresis Using Theraflex ECP for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)

Theraflex system in patients with refractory chronic graft versus host disease (cGVHD) after any type of hematopoietic stem cell transplantation or after donor lymphocyte infusion.

  • 3 views
  • 21 Jan, 2021
  • 7 locations
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

blood mononuclear cells collected via pheresis from a haploidentical family member - the procedure is analogous to giving a donor lymphocyte infusion outside of the setting of an allogeneic stem cell

gilbert's syndrome
cytopenias
stem cell transplantation
cellular therapy
blinatumomab
  • 0 views
  • 06 Jun, 2022
  • 1 location
Haploidentical HCT for Severe Aplastic Anemia

This study is a prospective, single center phase II clinical trial in which patients with Severe Aplastic Anemia (SAA) ) will receive a haploidentical transplantation. The purpose of this study is to learn more about newer methods of transplanting blood forming cells donated by a family member that is not …

red blood cell transfusion
ejection fraction
cyclophosphamide
glomerular filtration rate
fludarabine
  • 5 views
  • 07 Oct, 2022
  • 1 location
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other …

remission
tumor cells
myelodysplasia
mycophenolate mofetil
melphalan
  • 0 views
  • 21 Apr, 2022
  • 1 location
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

This clinical trial studies the use of reduced intensity chemotherapy and radiation therapy before donor stem cell transplant in treating patients with hematologic malignancies. Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine phosphate, before a donor stem cell transplant may help stop the growth of cancer cells. It …

serum bilirubin
total body irradiation
refractory anemia with excess blasts-2
hematologic malignancy
remission
  • 66 views
  • 29 Jun, 2022
  • 1 location